$CNSP
CNS Pharmaceuticals, Inc. Stock $cnsp

$cnsp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000168316823002086 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.359M	$2.153M	$5.967M
YoY Change	7.8%	140.15%	27.48%
% of Gross Profit
Research & Development	$3.568M	$3.349M	$9.300M
YoY Change	134.51%	76.6%	-0.5%
% of Gross Profit
Depreciation & Amortization	$1.279K	$2.380K	$11.76K
YoY Change	-62.16%	-31.81%	-10.05%
% of Gross Profit
Operating Expenses	$4.927M	$5.502M	$15.27M
YoY Change	77.1%	97.0%	8.84%
Operating Profit	-$4.927M		-$15.27M
YoY Change	56.44%		5.39%
Interest Expense	$5.436K	-$2.310K	$7.027K
YoY Change	-311.52%	3.13%	-175.64%
% of Operating Profit
Other Income/Expense, Net	-$5.436K		-$7.027K
YoY Change	111.85%		-24.32%
Pretax Income	-$4.932M	-$5.504M	-$15.27M
YoY Change	77.13%	96.92%	8.82%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.932M	-$5.504M	-$15.27M
YoY Change	77.13%	96.92%	8.82%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.59		-$11.22
Diluted Earnings Per Share	-$2.59	-$3.71	-$11.22
COMMON SHARES
Basic Shares Outstanding	2.226M shares	40.03M shares	1.362M shares
Diluted Shares Outstanding	1.906M shares		1.362M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.111M	$10.06M	$10.06M
YoY Change	-58.92%	100.93%	100.93%
Cash & Equivalents	$5.111M	$10.06M	$10.06M
Short-Term Investments
Other Short-Term Assets	$1.862M	$2.509M	$2.509M
YoY Change	-18.8%	1.47%	1.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.972M	$12.56M	$12.56M
YoY Change	-52.68%	68.03%	68.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.385K	$5.664K	$5.660K
YoY Change	-65.55%	-64.84%	-64.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$438.1K	$482.8K	$482.8K
YoY Change	-61.09%	-61.8%	-61.8%
Total Long-Term Assets	$442.5K	$488.5K	$488.5K
YoY Change	-61.14%	-61.84%	-61.84%
TOTAL ASSETS
Total Short-Term Assets	$6.972M	$12.56M	$12.56M
Total Long-Term Assets	$442.5K	$488.5K	$488.5K
Total Assets	$7.415M	$13.05M	$13.05M
YoY Change	-53.28%	49.05%	49.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.781M	$3.682M	$3.682M
YoY Change	467.79%	141.78%	141.78%
Accrued Expenses	$853.2K	$828.4K	$828.4K
YoY Change	177.92%	268.26%	268.26%
Deferred Revenue
YoY Change
Short-Term Debt	$289.1K	$449.9K	$410.0K
YoY Change	6.06%	5.61%	5.72%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.923M	$4.920M	$4.920M
YoY Change	266.87%	130.4%	130.4%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.923M	$4.920M	$4.920M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.923M	$4.920M	$4.920M
YoY Change	266.87%	130.4%	130.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.65M	-$50.72M
YoY Change		44.97%
Common Stock	$2.226K	$1.617K
YoY Change		-94.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.492M	$8.133M	$8.133M
YoY Change
Total Liabilities & Shareholders Equity	$7.415M	$13.05M	$13.05M
YoY Change	-53.28%	49.05%	49.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.932M	-$5.504M	-$15.27M
YoY Change	77.13%	96.92%	8.82%
Depreciation, Depletion And Amortization	$1.279K	$2.380K	$11.76K
YoY Change	-62.16%	-31.81%	-10.05%
Cash From Operating Activities	-$4.825M	-$2.305M	-$10.56M
YoY Change	56.79%	-28.78%	-22.02%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$4.422K
YoY Change		-100.0%	-176.9%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	-$4.422K
YoY Change		-100.0%	-23.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$16.04M
YoY Change			221.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$120.3K	5.333M	$15.61M
YoY Change	-101.14%	-6538.8%	246.26%
NET CHANGE
Cash From Operating Activities	-$4.825M	-2.305M	-$10.56M
Cash From Investing Activities		0.000	-$4.422K
Cash From Financing Activities	-$120.3K	5.333M	$15.61M
Net Change In Cash	-$4.945M	3.028M	$5.051M
YoY Change	-166.5%	-191.16%	-155.9%
FREE CASH FLOW
Cash From Operating Activities	-$4.825M	-$2.305M	-$10.56M
Capital Expenditures		$0.00	$4.422K
Free Cash Flow		-$2.305M	-$10.56M
YoY Change		-28.73%	-21.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001729427
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39126
CY2022	dei	Entity Registrant Name EntityRegistrantName	CNS Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2318545
CY2022	dei	City Area Code CityAreaCode	800
CY2022	dei	Local Phone Number LocalPhoneNumber	946-9185
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	CNSP
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 West Loop South
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 900
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77027
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	949052	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1617	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	949	usd
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	8780000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2226325	shares
CY2022	dei	Auditor Firm AuditorFirmId	206
CY2022	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10055407	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5004517	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2509238	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2472933	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12564645	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	7477450	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	482806	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	929688	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5664	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16109	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	334138	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	488470	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1279935	usd
CY2022Q4	us-gaap	Assets Assets	13053115	usd
CY2021Q4	us-gaap	Assets Assets	8757385	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3681900	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1981445	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	828391	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	224949	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	409968	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	387794	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4920259	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2594188	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4920259	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2594188	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1617325	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1617325	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	949052	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58846916	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41603791	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50715677	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35441543	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8132856	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6163197	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13053115	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8757385	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5967052	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4680840	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9300055	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9805075	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	15267107	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	14485915	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15267107	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14485915	usd
CY2022	us-gaap	Interest Expense InterestExpense	7027	usd
CY2021	us-gaap	Interest Expense InterestExpense	9285	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7027	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9285	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15274134	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14495200	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.22
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-16.50
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.22
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-16.50
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1361737	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	878443	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1361737	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	878443	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13947984	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4653821	usd
CY2021	CNSP	Stock Issued For Exercise Of Warrants Value StockIssuedForExerciseOfWarrantsValue	332750	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1723842	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14495200	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6163197	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16038093	usd
CY2022	CNSP	Stock Issued For Exercise Of Warrants Value StockIssuedForExerciseOfWarrantsValue	2734	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1202966	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15274134	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8132856	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15274134	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14495200	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1202966	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1723842	usd
CY2022	us-gaap	Depreciation Depreciation	11756	usd
CY2021	us-gaap	Depreciation Depreciation	13070	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	334138	usd
CY2021	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3111	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-860451	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1520281	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1700455	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1035115	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	603442	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-294855	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10557815	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13538309	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4422	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5748	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4422	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5748	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	427700	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	477490	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2734	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	332750	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16038093	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4653821	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15613127	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4509081	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5050890	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9034976	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5004517	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14039493	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10055407	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5004517	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8094	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9774	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	CNSP	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	0	usd
CY2021	CNSP	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	1756	usd
CY2022	CNSP	Prepaid Expenses Financedwith Note Payable PrepaidExpensesFinancedwithNotePayable	449874	usd
CY2021	CNSP	Prepaid Expenses Financedwith Note Payable PrepaidExpensesFinancedwithNotePayable	425990	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zEfOd9Gy0uq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><b>Note 1 – <span id="xdx_821_zyK73Y5n6DQ5">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 25, 2022, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30. The reverse stock split became effective on November 28, 2022 on a 1-for-30 basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"> </p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zDQ5ZcVq3xOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_86B_zjK0d60u0hJe">Use of Estimates in Financial Statement Presentation</span> -</b> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	9805407	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	449874	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0588	pure
CY2022Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-10-31
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	409968	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	425990	usd
CY2021Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.033	pure
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-09-30
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	387794	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-thirty (1:30) reverse stock split of the Company’s common stock and the filing of the Amendment to effectuate the reverse split. The reverse stock split became effective on November 28, 2022 on a 1-for-30 basis without any change in the par value per share, which remained at $0.001.
CY2022	CNSP	Nonaccountable Expense Allowance NonaccountableExpenseAllowance	50000	usd
CY2022	us-gaap	Legal Fees LegalFees	100000	usd
CY2022	CNSP	Clearing Fees ClearingFees	15950	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	334138	usd
CY2021	CNSP	Fair Value Of Common Stock On Measurement Date FairValueOfCommonStockOnMeasurementDate	$54.00 to $100.80 per share
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0028	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0128	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2817	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3072	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M23D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	9626	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2734	usd
CY2022	CNSP	Warrants Exercised Shares WarrantsExercisedShares	204957	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	332750	usd
CY2021	CNSP	Warrants Exercised Shares WarrantsExercisedShares	5041	shares
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	76087	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	800000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3206000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3042000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-194000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-100000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3012000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2942000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8603000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5860000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	715000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	533000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	628000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	715000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8690000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5678000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40966000	usd

Files In Submission

Name	View Source	Status
cnsp-20221231_cal.xml	Edgar Link	unprocessable
0001683168-23-002086-index-headers.html	Edgar Link	pending
0001683168-23-002086-index.html	Edgar Link	pending
0001683168-23-002086.txt	Edgar Link	pending
0001683168-23-002086-xbrl.zip	Edgar Link	pending
cnsp-20221231.xsd	Edgar Link	pending
cns_ex2301.htm	Edgar Link	pending
cns_ex3101.htm	Edgar Link	pending
cns_ex3102.htm	Edgar Link	pending
cns_ex3201.htm	Edgar Link	pending
cns_ex3202.htm	Edgar Link	pending
cns_i10k-2022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
cnsp-20221231_def.xml	Edgar Link	unprocessable
cnsp-20221231_lab.xml	Edgar Link	unprocessable
cnsp-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cns_i10k-2022_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNSP
CNS Pharmaceuticals, Inc. Stock $cnsp

2023 Q1 Form 10-K Financial Statement

#000168316823002086 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNSP CNS Pharmaceuticals, Inc. Stock $cnsp

2023 Q1 Form 10-K Financial Statement

#000168316823002086 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNSP
CNS Pharmaceuticals, Inc. Stock $cnsp